Genexine "Indonesian Minister of Health Visits Headquarters for COVID-19 Vaccine Cooperation"

Discussion on Cooperation for Development and Production of Vaccine Candidates

[Asia Economy Reporter Kim Ji-hee] Genexine announced on the 24th that Budi Gunadi Sadikin, Minister of Health of Indonesia, and others visited the headquarters during their visit to Korea to discuss cooperation on COVID-19 vaccine development and supply.

On that day, Minister Budi toured the vaccine development site and exchanged opinions with Genexine Chairman Sung Young-chul and President Woo Jung-won on specific cooperation matters for the development and production of the COVID-19 vaccine candidate 'GX-19N.' Additionally, they discussed vaccine development partnerships to prepare for problematic variant viruses and new pandemics in the future.

Genexine has been discussing clinical cooperation and vaccine supply with Indonesia from the early stages of vaccine development, based on its long-standing partnership with Kalbe Farma, Indonesia's largest pharmaceutical company, and the Indonesian government's active support for vaccine procurement.

Currently, Genexine has submitted an IND to the Indonesian Food and Drug Authority for the global Phase 2 and 3 clinical trials of GX-19N and is awaiting approval. In particular, the clinical trial scale is planned to be expanded from the initially planned 1,000 participants to 5,000. Furthermore, Genexine recently agreed with Kalbe Farma to supply 10 million doses of the vaccine to Indonesia as soon as emergency use authorization is obtained.

This content was produced with the assistance of AI translation services.